期刊文献+

复方左旋多巴联合普拉克索治疗帕金森病的疗效及对不良情绪、非运动症状的影响 被引量:9

Curative Effect of Compound Levodopa Combined with Pramipexole to Parkinson's Disease and Its Influence on Negative Emotions and Non-motor Symptoms
在线阅读 下载PDF
导出
摘要 目的 :研究复方左旋多巴联合普拉克索治疗帕金森病(PD)的效果及对不良情绪、非运动症状的影响。方法 :选取我院2014年3月-2016年5月收治的62例PD患者,采用随机数字表法分为对照组与观察组,各31例。对照组给予复方左旋多巴治疗,250 mg,tid,饭后口服,连续一周,观察患者耐受情况,且每周增加一次剂量,增加量为500 mg/d,每日最大用量不得超过6 g,增加用量后分5次/d服用;观察组给予复方左旋多巴联合治疗,复方左旋多巴250 mg,tid,饭后服用,连续一周;普拉克索片0.125 mg,tid,饭后服用,每日最大用量不得超过1.5 mg,连续用药一周;一周后普拉克索片增加用药剂量至0.25 mg/次,复方左旋多巴减量至125 mg/次,复方左旋多巴联合普拉克索片同时服用,tid。采用汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评分评价两组不良情绪,并比较两组治疗效果、非运动症状发生率。结果 :观察组治疗后HAMA和HAMD评分均低于对照组,差异具有统计学意义(P<0.05);观察组总有效率为90.32%,高于对照组45.16%,差异具有统计学意义(χ2=14.467,P<0.05);观察组尿频尿急、肢体水肿、痉挛等症状发生率显著低于对照组,差异具有统计学意义(P<0.05)。结论 :复方左旋多巴联合普拉克索治疗帕金森病可改善患者不良情绪和非运动症状,疗效显著。 Objective:To study curative effect of compound levodopa combined with pramipexole to Parkinson's disease(PD) and its influence on negative emotions and non-motor symptoms. Methods:62 cases of PD patients in our hospital were selected from March 2014 to May 2016, and the patients were divided into the control group and the observation group according to random number table, 31 cases in each group. The control group was treated with compound levodopa. The usage and dosage of compound levodopa was 250 mg, tid, oral administration after meals for a week. The tolerance of patient was observed, and the dose was increased once a week, the increment was 500 mg/d, the maximum dosage should not exceed 6 g per day, compound levodopa was divided into 5 times to take after increasing the dosage. The observation group was given compound levodopa combined with pramipexole treatment. The usage and dosage of levodopa was 250 mg, tid, oral administration after meals for a week; The usage and dosage of pramipexole was 0.125 mg, tid, oral administration after meals for a week, the maximum dosage should not exceed 1.5 mg per day. The dosage of pramipexole increased to 0.25 mg/times after a week, the dosage of levodopa reduced to 125 mg/times. Compound levodopa and pramipexole were taken together, tid. The negative emotions were evaluated by the Hamilton Anxiety Scale(HAMA) and Hamilton Depression Scale(HAMD) scores. Therapeutic effect and occurrence rate of non-motor symptoms were compared. Results:HAMA and HAMD scores of observation group after treatment were lower than those of the control group, the difference was statistically significant(P<0.05); the total effective rate of the observation group was 90.32% which was higher than 45.16% of the control group, the difference was statistically significant(χ2=14.467, P<0.05); the occurrence rate of urinary urgency, limb edema, spasm and other symptoms of observation group was significantly lower than those of the control group, the difference was statistically significant(P<0.05). Conclusion:Compound levodopa combined with pramipexole in treatment of PD can improve negative emotions and non-motor symptoms of patients, the curative effect was significant.
作者 程继伟
机构地区 新郑市人民医院
出处 《中国执业药师》 CAS 2017年第8期27-30,共4页 China Licensed Pharmacist
关键词 帕金森病 复方左旋多巴 普拉克索 不良情绪 非运动症状 Parkinson Disease Compound Levodopa Pramipexole Negative Emotions Non-motor Symptoms
  • 相关文献

参考文献6

二级参考文献65

  • 1Gallagher DA,Lees AJ,Schrag A.What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them[J]? Mov Disord,2010,25:2493-2500.
  • 2Barone P,Antonini A,Colosimo C,et al.The PRIAMO study:a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease[J].Mov Disord,2009,24:1641-1649.
  • 3Seki M,Takahashi K,Uematsu D,et al.Clinical features and varieties of non-motor fluctuations in Parkinson's disease:a Japanese multicenter study[J].Parkinsonism Relat Disord,2013,19:104-108.
  • 4Spica V,Pekmezovic T,Svetel M,et al.Prevalence of non-motor symptoms in young-onset versus lateonset Parkinson's disease[J].J Neurol,2013,260:131-137.
  • 5Braak H.Staging of brain pathology related to sporadic Parkinson's disease[J].Neurobiol Aging,2003,24:197-211.
  • 6HaehnerA,Boesveldt S,Berendse HW,et al.Prevalence of smell loss in Parkinson's disease-a multicenter study[J].Parkinsonism Relat Disord,2009,15:490-494.
  • 7Perez-Lloret S,Rey MV,Dellapina E,et al.Emerging analgesic drugs for Parkinson's disease[J].Expert Opin Emerg Drugs,2012,17:157-171.
  • 8Wen HB,Zhang ZX,Wang H,et al.Epidemiology and clinical phenomenology for Parkinson's disease with pain and fatigue[J].Parkinsonism Relat Disord,2012,18 Suppl 1:S222-225.
  • 9Farnikova K,Krobot A,Kanovsky P.Musculoskeletal problems as an initial manifestation of Parkinson's disease:a retrospective study[J].J Neurol Sci,2012,319:102-104.
  • 10Gjerstad MD,Wentzel Larsen T,Aarsland D,et al.Insomnia in Parkinson's disease:frequency and progression over time[J].J Neurol Neurosurg Psychiatry,2007,78:476-479.

共引文献124

同被引文献63

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部